利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

124 records (took 0.015 seconds)

    USE OF SPHINGOLIPIDS FOR REDUCING PLASMA CHOLESTEROL AND TRIACYLGLYCEROL LEVELS
    91.
    发明申请
    USE OF SPHINGOLIPIDS FOR REDUCING PLASMA CHOLESTEROL AND TRIACYLGLYCEROL LEVELS 审中-公开
    用于减少血浆胆固醇和三氯乙烯含量的SPHINGOLIPIDS的用途

    公开(公告)号：WO2004064820A3

    公开(公告)日：2004-09-30

    申请号：PCT/NL2004000048

    申请日：2004-01-20

    Applicant: TNO ,  NIEUWENHUIZEN WILLEM FERDINAND

    Inventor： NIEUWENHUIZEN WILLEM FERDINAND

    IPC: A23L1/30 ,  A23L2/40 ,  A61K31/13 ,  A61K31/133 ,  A61K31/14 ,  A61K31/688 ,  A61K45/06 ,  A61P9/10

    CPC classification number: A61K31/688 ,  A23L2/40 ,  A23L33/115 ,  A61K31/133 ,  A61K31/14 ,  A61K45/06

    Abstract: The present invention is in the field of cholesterol and triglyceride-lowering methods and compositions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside and/or sphingomyelin for lowering the cholesterol and triglyceride levels in a subject and to the use of sphingolipids as a plasma and/or serum cholesterol and triglyceride lowering agent. The invention also encompasses methods of treatment of subjects suffering from high plasma cholesterol and triglyceride levels, as well as food items and supplements with increased sphingolipid levels.

    Abstract translation: 本发明涉及胆固醇和甘油三酯降低方法和组合物领域。 特别地，本发明涉及鞘脂，更优选植物鞘氨醇，鞘氨醇，鞘氨醇，神经酰胺，脑脊液和/或鞘磷脂用于降低受试者中胆固醇和甘油三酯水平的用途，以及使用鞘脂作为血浆和/或 血清胆固醇和甘油三酯降低剂。 本发明还包括治疗患有高血浆胆固醇和甘油三酯水平的受试者以及具有增加的鞘脂水平的食物和补充剂的方法。

    USE OF SPHINGOLIPIDS FOR REDUCING PLASMA CHOLESTEROL AND TRIACYLGLYCEROL LEVELS
    92.
    发明申请
    USE OF SPHINGOLIPIDS FOR REDUCING PLASMA CHOLESTEROL AND TRIACYLGLYCEROL LEVELS 审中-公开
    降血脂药物降低血浆胆固醇和三酰甘油水平

    公开(公告)号：WO2004064820A2

    公开(公告)日：2004-08-05

    申请号：PCT/NL2004/000048

    申请日：2004-01-20

    Applicant: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO ,  NIEUWENHUIZEN, Willem, Ferdinand

    Inventor： NIEUWENHUIZEN, Willem, Ferdinand

    IPC: A61K31/13

    CPC classification number: A61K31/688 ,  A23L2/40 ,  A23L33/115 ,  A61K31/133 ,  A61K31/14 ,  A61K45/06

    Abstract: The present invention is in the field of cholesterol and triglyceride-lowering methods and compositions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside and/or sphingomyelin for lowering the cholesterol and triglyceride levels in a subject and to the use of sphingolipids as a plasma and/or serum cholesterol and triglyceride lowering agent. The invention also encompasses methods of treatment of subjects suffering from high plasma cholesterol and triglyceride levels, as well as food items and supplements with increased sphingolipid levels.

    Abstract translation: 本发明属于胆固醇和甘油三酯降低方法和组合物领域。 特别地，本发明涉及鞘脂类，更优选植物鞘氨醇，鞘氨醇，二氢鞘氨醇，神经酰胺，脑苷脂和/或鞘磷脂用于降低受试者中胆固醇和甘油三酯水平的用途，以及鞘脂类作为血浆和/或 血清胆固醇和甘油三酯降低剂。 本发明还包括治疗患有高血浆胆固醇和甘油三酯水平的受试者的方法，以及具有增加的鞘脂水平的食物和补充剂。

    PROTECTION OF THE FEMALE REPRODUCTIVE SYSTEM FROM NATURAL AND ARTIFICIAL INSULTS
    93.
    发明申请
    PROTECTION OF THE FEMALE REPRODUCTIVE SYSTEM FROM NATURAL AND ARTIFICIAL INSULTS 审中-公开
    保护女性生殖系统从自然和人为的绝食

    公开(公告)号：WO2004014271A1

    公开(公告)日：2004-02-19

    申请号：PCT/US2003/025233

    申请日：2003-08-12

    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  MASSACHUSETTS GENERAL HOSPITAL ,  TILLY, Jonathan, L. ,  KOLESNICK, Richard, N.

    Inventor： TILLY, Jonathan, L. ,  KOLESNICK, Richard, N.

    IPC: A61F13/00

    CPC classification number: A61K31/688 ,  A61K31/00 ,  A61K31/66 ,  A61K31/661 ,  A61K31/685

    Abstract: Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-l-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.

    Abstract translation: 描述了通过向妇女施用包含拮抗一种或多种酸性鞘磷脂酶（ASMase）基因产物的组合物的组合物来保护雌性生殖系统免受天然和人造侮辱的方法。 具体来说，本文公开的方法用于保护妇女的种系免受包括化学疗法或放射治疗在内的癌症治疗方案的损害。 一方面，通过向妇女施用含有鞘氨醇-1-磷酸的组合物或其类似物，该方法保留，增强或恢复妇女的卵巢功能。 还公开了预防或改善绝经综合征和改善体外受精技术的方法。

    ORAL COMBINATIONS OF HYDROXOCOBALAMIN AND FOLIC ACID
    94.
    发明申请
    ORAL COMBINATIONS OF HYDROXOCOBALAMIN AND FOLIC ACID 审中-公开
    羟基卡波胺和氟酸的口服组合

    公开(公告)号：WO0056295A3

    公开(公告)日：2002-03-28

    申请号：PCT/GB0001093

    申请日：2000-03-23

    Applicant: KILGOWAN LTD

    Inventor： HORROBIN DAVID FREDERICK ,  GOUAILLE CHRISTINA

    IPC: A61K45/06 ,  A61K31/70 ,  A23L1/302 ,  A61P43/00

    CPC classification number: A61K31/688 ,  A61K31/505 ,  A61K31/714 ,  A61K45/06 ,  A61K31/50 ,  A61K2300/00

    Abstract: A variety of conditions is known wherein vitamin B12 is deficient, or wherein the administration of vitamin B12 is beneficial. Classically, once detected and if appropriate, these have been treated by the parenteral administration of vitamin B12 as oral administration is believed to be ineffective. Available oral preparations of vitamin B12 all contain cyanocobalamin which is less desirable than hydroxocobalamin. In accordance with the invention, effective oral formulations are provided which include, in addition to the hydroxocobalamin, folic acid or other folate precursor. The formulation for oral administration should be such as to provide, for a given daily dose, 0.5 to 50 mg hydroxocobalamin and 0.5 to 50 mg folic acid.

    Abstract translation: 已知有多种维生素B12缺乏的条件，或其中维生素B12的施用是有益的。 一经检测，如果合适，这些已经通过肠外给药维生素B12治疗，因为口服给药被认为是无效的。 维生素B12的口服制剂都含有与羟钴胺素不太相似的氰钴胺素。 根据本发明，提供了有效的口服制剂，除了羟钴胺素，叶酸或其它叶酸前体之外还包括。 用于口服给药的制剂应该为给定的日剂量提供0.5至50mg羟钴胺素和0.5至50mg叶酸。

    ORAL COMBINATIONS OF HYDROXOCOBALAMIN AND FOLIC ACID
    95.
    发明申请
    ORAL COMBINATIONS OF HYDROXOCOBALAMIN AND FOLIC ACID 审中-公开
    羟基卡波胺和氟酸的口腔组合

    公开(公告)号：WO00056295A2

    公开(公告)日：2000-09-28

    申请号：PCT/GB2000/001093

    申请日：2000-03-23

    IPC: A61K45/06 ,  A61K31/00

    CPC classification number: A61K31/688 ,  A61K31/505 ,  A61K31/714 ,  A61K45/06 ,  A61K31/50 ,  A61K2300/00

    Abstract: A variety of conditions is known wherein vitamin B12 is deficient, or wherein the administration of vitamin B12 is beneficial. Classically, once detected and if appropriate, these have been treated by the parenteral administration of vitamin B12 as oral administration is believed to be ineffective. Available oral preparations of vitamin B12 all contain cyanocobalamin which is less desirable than hydroxocobalamin. In accordance with the invention, effective oral formulations are provided which include, in addition to the hydroxocobalamin, folic acid or other folate precursor. The formulation for oral administration should be such as to provide, for a given daily dose, 0.5 to 50 mg hydroxocobalamin and 0.5 to 50 mg folic acid.

    Abstract translation: 已知有多种维生素B12缺乏的情况，或其中维生素B12的给药是有益的。 一经检测，如果合适，这些已经通过肠胃外给药维生素B12治疗，因为口服给药被认为是无效的。 维生素B12的口服制剂都含有与羟钴胺素不太相似的氰钴胺素。 根据本发明，提供了有效的口服制剂，除了羟钴胺素，叶酸或其他叶酸前体之外还包括。 用于口服给药的制剂应该为给定的日剂量提供0.5至50mg羟钴胺素和0.5至50mg叶酸。

    COMPOSITIONS FOR MODULATING INTRACELLULAR INOSITOL TRISPHOSPHATE CONCENTRATION AND USES THEREOF
    97.
    发明申请
    COMPOSITIONS FOR MODULATING INTRACELLULAR INOSITOL TRISPHOSPHATE CONCENTRATION AND USES THEREOF 审中-公开
    用于调节细胞内磷酸三钙浓度的组合物及其用途

    公开(公告)号：WO1997022251A1

    公开(公告)日：1997-06-26

    申请号：PCT/US1996020494

    申请日：1996-12-23

    Applicant: AYURCORE, INC.

    Inventor： AYURCORE, INC. ,  ROSENBERG, Abraham

    IPC: A01N43/04

    CPC classification number: C12Q1/44 ,  A61K31/13 ,  A61K31/685 ,  A61K31/688 ,  A61K31/70 ,  A61K31/7032 ,  G01N2333/916 ,  G01N2405/10

    Abstract: Compositions and methods for the modulation of aberrant inositol trisphosphate concentration in neurons is disclosed. Inositol trisphosphate stimulates an increase in intraneuronal calcium ion concentration which can, if unregulated, lead to acute neurotoxicities following such insults as brain seizures, and brain anoxia/ischemia; and lead to chronic neurotoxicities in such diseases as Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Inhibited inositol trisphosphate production results in aberrantly low calcium ion levels leading to neuronal apoptosis. The figure illustrates conversion of phosphitidyl inositol 4,5-biphosphate into diacylglycerol and inositol trisphosphate.

    Abstract translation: 公开了用于调节神经元中异常肌醇三磷酸浓度的组合物和方法。 肌醇三磷酸盐刺激内源性钙离子浓度的增加，如果不受调节，则可以在脑癫痫发作和脑缺氧/缺血之后引起急性神经毒性; 并导致诸如阿尔茨海默病，亨廷顿病，帕金森病和肌萎缩性侧索硬化等疾病中的慢性神经毒性。 抑制肌醇三磷酸盐产生导致异常低的钙离子水平导致神经元凋亡。 该图示出了将磷脂酰肌醇4,5-二磷酸转化为二酰基甘油和肌醇三磷酸酯。

Patent Agency Ranking